Under the agreement Mitsubishi is responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron significant royalties on commercial sales in Japan.
Nuron acquired HibTITER (Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate)) from Wyeth, a wholly owned subsidiary of Pfizer.
HibTITER was one of the first glycoconjugate technology vaccines for humans on the market and was responsible for reducing the incidence of Hib disease in children.
Nuron CEO Shankar Musunuri said the agreement provides them with additional resources to accelerate their re-launch strategy of the vaccine in the US market.